Ding Sentai, Wu Chenrui, Cao Jishuang, Lyu Jiaju
Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Curr Urol. 2025 Jan;19(1):39-42. doi: 10.1097/CU9.0000000000000263. Epub 2024 Nov 14.
Immunotherapy has become a standard treatment for patients with advanced urothelial carcinoma, and neoadjuvant immunotherapy is currently being extensively explored. This review highlights the initial findings and key clinical therapeutic insights on immune checkpoint inhibitors in the early treatment of muscle-invasive bladder cancer across diverse patient populations. Most available literature consists of clinical investigations involving small sample, single-arm phase II trials, with the primary endpoint being the pathologic complete response rate. Early results of immune checkpoint inhibitors in the neoadjuvant treatment of bladder cancer have demonstrated promising efficacy. However, these findings require confirmation in large phase III clinical trials, with particular emphasis on long-term survival benefits and identifying patients who respond to treatment.
免疫疗法已成为晚期尿路上皮癌患者的标准治疗方法，新辅助免疫疗法目前正在广泛探索中。本综述重点介绍了免疫检查点抑制剂在不同患者群体早期治疗肌肉浸润性膀胱癌中的初步发现和关键临床治疗见解。现有大多数文献包括涉及小样本、单臂II期试验的临床研究，主要终点是病理完全缓解率。免疫检查点抑制剂在膀胱癌新辅助治疗中的早期结果已显示出有前景的疗效。然而，这些发现需要在大型III期临床试验中得到证实，尤其要关注长期生存获益以及确定对治疗有反应的患者。
